<DOC>
	<DOCNO>NCT00215644</DOCNO>
	<brief_summary>The purpose study compare effectiveness safety experimental treatment matuzumab ECX chemotherapy , ECX chemotherapy . Subjects invite take part metastatic cancer esophagus ( gullet ) stomach .</brief_summary>
	<brief_title>MATRIX EG ( Matuzumab Treatment With ECX Esophago-Gastric Cancer )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically confirm gastric adenocarcinoma adenocarcinoma lower third esophagus metastatic disease immunohistological evidence EGFR expression archive tissue ECOG PS 01 least 1 measurable lesion ( modify WHO criterion ) previous chemotherapy , unless neoadjuvant adjuvant therapy complete &gt; 12 month prior study treatment radiotherapy major surgery within 4 week prior treatment brain metastases peripheral neuropathy ototoxicity &gt; /= Grade 2 ( NCICTC V3 ) abnormal ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Esophagus</keyword>
	<keyword>Gastric</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>EGFR</keyword>
	<keyword>matuzumab</keyword>
	<keyword>EMD 72000</keyword>
	<keyword>randomize</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>cisplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>Metastatic Esophago-Gastric cancer</keyword>
</DOC>